Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis

Sponsor
Lahore General Hospital
Study ID
NCT07261306
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Methotrexate — DRUG
    Methotrexate is an antifolate drug work by inhibiting enzyme dihydrofolate reductase and inhibit cell proliferation and play a role in psoriasis treatment
  • Tofacitinib — DRUG
    Tofacitinib is janus kinase inhibitor and have role in psoriasis

Study Details

Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study

Key Dates

Start date
Aug 29, 2025
Status verified
Aug 2025
Primary completion
Dec 10, 2025
Completion
Dec 25, 2025

Study Design

Enrollment
75 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Group mTX
    Methotrexate is a modified antirheumatic drug work by inhibiting dihydrofolate reductase
  • Active Comparator: Tofacitinib
    Tofacitinib is janus kinase inhibitor and had a role in treatment of psoriasis and psoriatic arthritis

Primary Outcome Measure

Efficacy Achievement [ Time Frame: Baseline to Week 12 of treatment ]

Central Contacts

Related Studies